EO-2463 is under clinical development by Enterome Bioscience and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EO-2463’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EO-2463 is under development for the treatment of B-cell malignancies like B-cell leukemias and follicular lymphoma (FL) or marginal zone lymphoma (MZL). The drug candidate is next-generation microbiome-derived vaccine acts by targeting novel antigens (CD20, CD22, CD37 and BAFF-R) named onco-mimics. The drug candidate is developed based on enterome oncomimicry platform. It is administered through subcutaneous route.
Enterome Bioscience overview
Enterome Bioscience (Enterome) is a drug development company which develops medical tests, and companion diagnostics to develop the management of microbiome-related diseases. The company develops medical tests based on its metagenotype technology platform that helps to identify microbiome-based biomarkers and screen for microbiome-derived molecules. It also develops new diagnostic products for patient classification and forecasting treatment response. Enterome provides microbiome-derived molecules as drug candidates. The company develops drugs for treatment of microbiome-related diseases which include metabolic, inflammatory bowel diseases, and central nervous system linked diseases. Enterome is headquartered in Paris, France.
For a complete picture of EO-2463’s drug-specific PTSR and LoA scores, buy the report here.